[Tolerance of famotidine. Study of network of sentinel physicians in pharmaco-vigilance].
This paper presents the results of an intensive surveillance based on a network of general practitioners and following 200 patients treated by famotidine 40 mg per day during 6 to 8 weeks. Four patients with a previous experience of adverse reaction to another H2 antagonist did not relapse with famotidine. None interaction was reported with drugs such as beta-blockers, oral anticoagulants, theophylline, benzodiazepines, calcium antagonists. Twenty four clinical side effects were reported; For 5 patients (2.5%) the treatment had to be stopped. The most common side effects were neurological. The results are compared with those of previously published studies.
Chichmanian
R M
RM
Centre Régional de Pharmacovigilance, Hôpital Pasteur, Nice.
Mignot
G
G
Spreux
A
A
Jean-Girard
C
C
Hofliger
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D004812:Epidemiologic Methods; D005194:Family Practice; D015738:Famotidine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced
D015738:Famotidine
Tolérance de la famotidine. Etude du réseau médecins sentinelles en pharmacovigilance.